Most Promising Approaches to Improve Stroke Outcomes: The Stroke Treatment Academic Industry Roundtable XII Workshop

Abstract

The Stroke Treatment Academic Industry Roundtable XII included a workshop to discuss the most promising approaches to improve outcome from acute stroke. The workshop brought together representatives from academia, industry, and government representatives. The discussion examined approaches in 4 epochs: pre-reperfusion, reperfusion, post-reperfusion, and access to acute stroke interventions. The participants identified areas of priority for developing new and existing treatments and approaches to improve stroke outcomes. Although many advances in acute stroke therapy have been achieved, more work is necessary for reperfusion therapies to benefit the most possible patients. Prioritization of promising approaches should help guide the use of resources and investigator efforts.

A promising frontier: targeting NETs for stroke treatment breakthroughs

“…This lack of clinical effectiveness of reperfusion can be attributed to various factors, such as irreversible infarction, infarct evolution, haemorrhagic transformation, cerebral oedema, microvascular occlusion, and suboptimal postreperfusion care [ 143 ]. As a result, the Stroke Treatment Academic Industry Roundtable XII convened to address strategies for improving acute stroke outcomes [ 144 ]. Opportunities exist for improving poststroke functional outcomes through the reduction of treatment duration in eligible patients prior to reperfusion [ 145 , 146 ], as well as the timely administration of neuroprotective agents following stroke onset [ 147 ].…”

Exploring novel experimental treatments for major neurodegenerative disorders

“…For instance, recanalization approaches for ischemic stroke have a narrow therapeutic time window, rendering them inaccesible for the majority of patients. Current work therefore focuses on improving acute stroke management including adjuvant neuroprotective or immunomodulative interventions to allow more patients to benefit from recanalization 1 . Similarly, recent approaches to target amyloid β (Aβ) plaques using monoclonal antibodies in AD are only effective in the early stages of the disease.…”

“…Current work therefore focuses on improving acute stroke management including adjuvant neuroprotective or immunomodulative interventions to allow more patients to benefit from recanalization. 1 Similarly, recent approaches to target amyloid β (Aβ) plaques using monoclonal antibodies in AD are only effective in the early stages of the disease. However, the overall therapeutic impact remains modest, accompanied by the potential of severe side effects.…”